CY1107901T1 - Μεθοδος προσδιορισμου για ασθενεια alzheimer - Google Patents
Μεθοδος προσδιορισμου για ασθενεια alzheimerInfo
- Publication number
- CY1107901T1 CY1107901T1 CY20081100267T CY081100267T CY1107901T1 CY 1107901 T1 CY1107901 T1 CY 1107901T1 CY 20081100267 T CY20081100267 T CY 20081100267T CY 081100267 T CY081100267 T CY 081100267T CY 1107901 T1 CY1107901 T1 CY 1107901T1
- Authority
- CY
- Cyprus
- Prior art keywords
- beta
- alzheimer
- determination method
- preclinical
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31322101P | 2001-08-17 | 2001-08-17 | |
| US31322401P | 2001-08-17 | 2001-08-17 | |
| US33498701P | 2001-10-23 | 2001-10-23 | |
| EP02766022A EP1416965B8 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107901T1 true CY1107901T1 (el) | 2013-09-04 |
Family
ID=27405654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100267T CY1107901T1 (el) | 2001-08-17 | 2008-03-07 | Μεθοδος προσδιορισμου για ασθενεια alzheimer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1416965B8 (enExample) |
| JP (2) | JP4511830B2 (enExample) |
| AT (1) | ATE381346T1 (enExample) |
| CA (1) | CA2457145C (enExample) |
| CY (1) | CY1107901T1 (enExample) |
| DE (1) | DE60224200T2 (enExample) |
| DK (1) | DK1416965T3 (enExample) |
| ES (1) | ES2295401T3 (enExample) |
| PT (1) | PT1416965E (enExample) |
| WO (1) | WO2003015617A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100767146B1 (ko) | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| ES2391905T3 (es) | 2001-08-17 | 2012-11-30 | Washington University | Método de ensayo para la enfermedad de alzheimer |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DE602004027348D1 (de) | 2003-02-10 | 2010-07-08 | Applied Molecular Evolution | Abeta-bindende moleküle |
| EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| ES2535641T3 (es) | 2007-01-18 | 2015-05-13 | Eli Lilly & Company | Amiloide beta Fab pegilado |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2010093001A1 (ja) * | 2009-02-13 | 2010-08-19 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
| JP5745531B2 (ja) | 2009-12-11 | 2015-07-08 | アラクロン・ビオテック・エセ・エレ | アミロイドベータペプチドの検出を改善するための方法および試薬 |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| CA2931220A1 (en) * | 2013-11-20 | 2015-05-28 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
| CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
| KR102496845B1 (ko) * | 2018-08-08 | 2023-02-08 | 서울대학교산학협력단 | 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0667959T3 (da) * | 1992-10-26 | 2003-12-08 | Elan Pharm Inc | Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6730778B2 (en) * | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
-
2002
- 2002-08-16 CA CA2457145A patent/CA2457145C/en not_active Expired - Fee Related
- 2002-08-16 ES ES02766022T patent/ES2295401T3/es not_active Expired - Lifetime
- 2002-08-16 EP EP02766022A patent/EP1416965B8/en not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026321 patent/WO2003015617A2/en not_active Ceased
- 2002-08-16 AT AT02766022T patent/ATE381346T1/de active
- 2002-08-16 DE DE60224200T patent/DE60224200T2/de not_active Expired - Lifetime
- 2002-08-16 JP JP2003520382A patent/JP4511830B2/ja not_active Expired - Lifetime
- 2002-08-16 PT PT02766022T patent/PT1416965E/pt unknown
- 2002-08-16 DK DK02766022T patent/DK1416965T3/da active
-
2008
- 2008-03-07 CY CY20081100267T patent/CY1107901T1/el unknown
-
2009
- 2009-09-09 JP JP2009208372A patent/JP5162553B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK1416965T3 (da) | 2008-05-05 |
| JP4511830B2 (ja) | 2010-07-28 |
| JP2004538477A (ja) | 2004-12-24 |
| CA2457145C (en) | 2010-12-21 |
| ATE381346T1 (de) | 2008-01-15 |
| PT1416965E (pt) | 2008-04-01 |
| EP1416965B1 (en) | 2007-12-19 |
| WO2003015617A2 (en) | 2003-02-27 |
| CA2457145A1 (en) | 2003-02-27 |
| HK1061960A1 (en) | 2004-10-15 |
| ES2295401T3 (es) | 2008-04-16 |
| EP1416965A2 (en) | 2004-05-12 |
| JP5162553B2 (ja) | 2013-03-13 |
| DE60224200D1 (de) | 2008-01-31 |
| DE60224200T2 (de) | 2008-07-10 |
| WO2003015617A3 (en) | 2004-01-29 |
| EP1416965A4 (en) | 2005-11-02 |
| EP1416965B8 (en) | 2008-02-13 |
| JP2010044078A (ja) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107901T1 (el) | Μεθοδος προσδιορισμου για ασθενεια alzheimer | |
| EP1944040A3 (en) | Assay method for Alzheimer's disease | |
| DK1391215T3 (da) | Automatiseret infusionssystem med kalkulator til dosishastighed | |
| WO2000018954A3 (en) | Use of pex in the treatment of metabolic bone diseases | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| DE60239522D1 (de) | Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays | |
| AU4694499A (en) | Trace level detection of analytes using artificial olfactometry | |
| ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
| ATE108666T1 (de) | Ultraschall-kontrastmittel, verfahren zu ihrer herstellung und verwendung derselben als diagnostika und therapeutika. | |
| ATE388167T1 (de) | Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 | |
| ES2138729T3 (es) | Metodos de diagnostico de la preeclampsia. | |
| DE69626683D1 (de) | Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten | |
| EP0674661A4 (en) | TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS. | |
| ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
| ATE159300T1 (de) | Monoklonale antikörper gegen menschliches ige | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| FI973469A0 (fi) | Menetelmä tekijän IX valmistamiseksi biologisista lähteistä | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
| BR0113646A (pt) | Tratamento de distúrbios inflamatórios | |
| WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
| AU2002211577A1 (en) | Protecting therapeutic compositions from host-mediated inactivation | |
| AU2002366555A1 (en) | Diagnostic for early stage alzheimer's disease | |
| AU4098201A (en) | Method for diagnosing efficacy of xenotypic antibody therapy | |
| AU2003208857A1 (en) | Diagnostic and therapeutic use of caps |